{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:38:42Z","timestamp":1788928722599,"version":"build-2803163510"},"publisher-location":"Cham","reference-count":40,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030203146","type":"print"},{"value":"9783030203153","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/978-3-030-20315-3_1","type":"book-chapter","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T01:05:44Z","timestamp":1563325544000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Thrombosis and Hemostasis in Cancer. Scope of the Problem and Overview"],"prefix":"10.1007","author":[{"given":"Gerald","family":"Soff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,18]]},"reference":[{"issue":"15","key":"1_CR1","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMcpc020117","volume":"347","author":"Martin A. Samuels","year":"2002","unstructured":"Samuels MA, King ME, Balis U (2002) Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31-2002. A 61-year-old man with headache and multiple infarcts. N Engl J Med 347(15):1187\u20131194","journal-title":"New England Journal of Medicine"},{"key":"1_CR2","first-page":"188","volume":"1","author":"Bouillaud S De","year":"1823","unstructured":"De Bouillaud S (1823) l\u00d5Obliteration des veines et de son influence sur la formation des hydropisies partielles: consideration sur la hydropisies passive et general. Arch Gen Med 1:188\u2013204","journal-title":"Arch Gen Med"},{"issue":"3","key":"1_CR3","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5(3):632\u2013634","journal-title":"J Thromb Haemost"},{"issue":"29","key":"1_CR4","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1200\/JCO.2009.22.8197","volume":"27","author":"A Falanga","year":"2009","unstructured":"Falanga A, Marchetti M (2009) Venous thromboembolism in the hematologic malignancies. J Clin Oncol 27(29):4848\u20134857","journal-title":"J Clin Oncol"},{"issue":"7","key":"1_CR5","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1055\/s-2006-951297","volume":"32","author":"A Piccioli","year":"2006","unstructured":"Piccioli A, Falanga A, Baccaglini U, Marchetti M, Prandoni P (2006) Cancer and venous thromboembolism. Semin Thromb Hemost 32(7):694\u2013699","journal-title":"Semin Thromb Hemost"},{"issue":"7783","key":"1_CR6","first-page":"7932","volume":"2","author":"GJ Gasic","year":"1972","unstructured":"Gasic GJ, Gasic TB, Murphy S (1972) Anti-metastatic effect of aspirin. Lancet 2(7783):7932\u20137933","journal-title":"Lancet"},{"key":"1_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1073\/pnas.61.1.46","volume":"61","author":"GJ Gasic","year":"1968","unstructured":"Gasic GJ, Gasic TB, Stewart CC (1968) Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 61:46\u201352","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"1_CR8","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.amjmed.2017.01.022","volume":"130","author":"A Leader","year":"2017","unstructured":"Leader A, Zelikson-Saporta R, Pereg D, Spectre G, Rozovski U, Raanani P et al (2017) The effect of combined aspirin and clopidogrel treatment on cancer incidence. Am J Med 130(7):826\u2013832","journal-title":"Am J Med"},{"key":"1_CR9","doi-asserted-by":"crossref","unstructured":"Liang HW, Yan X, Pan Y, Wang YS, Wang N, Li LM, et al (2015) MicroRNA-223 delivered by platelet-derived microvesicles promotes lung cancer cell invasion via targeting tumor suppressor EPB41L3. Mol Cancer 14","DOI":"10.1186\/s12943-015-0327-z"},{"issue":"11","key":"1_CR10","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1073\/pnas.1319269111","volume":"111","author":"SS Donatelli","year":"2014","unstructured":"Donatelli SS, Zhou JM, Gilvary DL, Eksioglu EA, Chen XH, Cress WD et al (2014) TGF-beta-inducible microRNA-183 silences tumor-associated natural killer cells. Proc Natl Acad Sci USA 111(11):4203\u20134208","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"1_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1160\/th15-05-0389","volume":"115","author":"B Laffont","year":"2016","unstructured":"Laffont B, Corduan A, Rousseau M, Duchez AC, Lee CHC, Boilard E et al (2016) Platelet microparticles reprogram macrophage gene expression and function. Thromb Haemost 115(2):311\u2013323","journal-title":"Thromb Haemost"},{"issue":"57","key":"1_CR12","doi-asserted-by":"publisher","first-page":"97464","DOI":"10.18632\/oncotarget.22136","volume":"8","author":"ML Tang","year":"2017","unstructured":"Tang ML, Jiang L, Lin YY, Wu XL, Wang K, He QZ et al (2017) Platelet microparticle-mediated transfer of miR-939 to epithelial ovarian cancer cells promotes epithelial to mesenchymal transition. Oncotarget 8(57):97464\u201397475","journal-title":"Oncotarget"},{"issue":"1","key":"1_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/01.sla.0000193959.44677.48","volume":"243","author":"G Agnelli","year":"2006","unstructured":"Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E et al (2006) A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 243(1):89\u201395","journal-title":"Ann Surg"},{"issue":"25","key":"1_CR14","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","volume":"29","author":"RA Moore","year":"2011","unstructured":"Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE et al (2011) High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 29(25):3466\u20133473","journal-title":"J Clin Oncol"},{"issue":"23","key":"1_CR15","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.1200\/JCO.2008.19.4274","volume":"27","author":"N Starling","year":"2009","unstructured":"Starling N, Rao S, Cunningham D, Iveson T, Nicolson M, Coxon F et al (2009) Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 27(23):3786\u20133793","journal-title":"J Clin Oncol"},{"issue":"10","key":"1_CR16","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902\u20134907","journal-title":"Blood"},{"issue":"7","key":"1_CR17","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa1108898","volume":"366","author":"G Agnelli","year":"2012","unstructured":"Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P et al (2012) Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 366(7):601\u2013609","journal-title":"N Engl J Med"},{"issue":"10","key":"1_CR18","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","volume":"10","author":"G Agnelli","year":"2009","unstructured":"Agnelli G, Gussoni G, Bianchini C, Verso M, Mandala M, Cavanna L et al (2009) Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 10(10):943\u2013949","journal-title":"Lancet Oncol"},{"key":"1_CR19","doi-asserted-by":"crossref","unstructured":"Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, et al (2018) Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med","DOI":"10.1056\/NEJMoa1814468"},{"key":"1_CR20","doi-asserted-by":"crossref","unstructured":"Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, et al (2018) Rivaroxaban thromboprophylaxis in high-risk ambulatory cancer patients receiving systemic therapy: results of a randomized clinical trial (CASSINI) (Abstract). Blood","DOI":"10.1182\/blood-2018-120738"},{"key":"1_CR21","doi-asserted-by":"crossref","unstructured":"Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, et al (2010) Prediction of venous thromboembolism in cancer patients. Blood","DOI":"10.1182\/blood-2010-02-270116"},{"issue":"6","key":"1_CR22","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1001\/archinte.160.6.809","volume":"160","author":"JA Heit","year":"2000","unstructured":"Heit JA, Silverstein MD, Mohr DN, Petterson TM, O\u2019Fallon WM, Melton LJ 3rd (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160(6):809\u2013815","journal-title":"Arch Intern Med"},{"issue":"3","key":"1_CR23","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/cncr.27772","volume":"119","author":"AA Khorana","year":"2013","unstructured":"Khorana AA, Dalal M, Lin J, Connolly GC (2013) Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 119(3):648\u2013655","journal-title":"Cancer"},{"issue":"34","key":"1_CR24","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.1200\/JCO.2007.14.1283","volume":"25","author":"GH Lyman","year":"2007","unstructured":"Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M et al (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25(34):5490\u20135505","journal-title":"J Clin Oncol"},{"issue":"19","key":"1_CR25","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1056\/NEJMc053530","volume":"354","author":"R Knight","year":"2006","unstructured":"Knight R, DeLap RJ, Zeldis JB (2006) Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354(19):2079\u20132080","journal-title":"N Engl J Med"},{"issue":"4","key":"1_CR26","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","volume":"119","author":"A. Larocca","year":"2011","unstructured":"Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, et al (2012) Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 119(4):933\u2013939; quiz 1093","journal-title":"Blood"},{"issue":"29","key":"1_CR27","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.1200\/JCO.2009.22.3875","volume":"27","author":"M Zangari","year":"2009","unstructured":"Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ (2009) Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 27(29):4865\u20134873","journal-title":"J Clin Oncol"},{"issue":"10","key":"1_CR28","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","volume":"100","author":"P Prandoni","year":"2002","unstructured":"Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100(10):3484\u20133488","journal-title":"Blood"},{"issue":"2","key":"1_CR29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AY Lee","year":"2003","unstructured":"Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146\u2013153","journal-title":"N Engl J Med"},{"issue":"9","key":"1_CR30","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.6004\/jnccn.2015.0133","volume":"13","author":"Michael B. Streiff","year":"2015","unstructured":"Streiff MB, Holmstrom B, Ashrani A, Bockenstedt PL, Chesney C, Eby C, et al (2015) Cancer-associated venous thromboembolic disease, version 1.2015. J Natl Compr Canc Netw 13(9):1079\u20131095","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"1_CR31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.thromres.2016.07.013","volume":"145","author":"AA Khorana","year":"2016","unstructured":"Khorana AA, Yannicelli D, McCrae KR, Milentijevic D, Crivera C, Nelson WW et al (2016) Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed? Thromb Res 145:51\u201353","journal-title":"Thromb Res"},{"issue":"2","key":"1_CR32","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s11239-016-1429-1","volume":"43","author":"S Mantha","year":"2017","unstructured":"Mantha S, Laube E, Miao Y, Sarasohn DM, Parameswaran R, Stefanik S et al (2017) Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study. J Thromb Thrombolysis 43(2):166\u2013171","journal-title":"J Thromb Thrombolysis"},{"issue":"7","key":"1_CR33","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D et al (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378(7):615\u2013624","journal-title":"N Engl J Med"},{"key":"1_CR34","unstructured":"Young A, Marshall A, Thirlwall J, Hill C, Hale D, Dunn J, et al (2017) Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the select-D pilot trial. In: ASH 59th annual meeting & exposition. Blood, Atlanta, GA, p. 625"},{"key":"1_CR35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.thromres.2016.12.016","volume":"150","author":"JA Ross","year":"2017","unstructured":"Ross JA, Miller MM, Rojas Hernandez CM (2017) Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: a retrospective analysis. Thromb Res 150:86\u201389","journal-title":"Thromb Res"},{"key":"1_CR36","doi-asserted-by":"crossref","unstructured":"Seo SR, M-H, Kang Y-K, Kim K-P, Chang H-M, Ryoo B-Y, Kim SB, Lee J-L, Park SR (2016) Oral rivaroxaban versus subcutaneous low molecular weight heparin treatment for venous thromboembolism in patients with upper gastrointestinal, hepatobiliary and pancreatic cancer. Ann Oncol 27(Suppl 6):695","DOI":"10.1093\/annonc\/mdw371.87"},{"issue":"5","key":"1_CR37","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ajh.25059","volume":"93","author":"MB Streiff","year":"2018","unstructured":"Streiff MB, Milentijevic D, McCrae K, Yannicelli D, Fortier J, Nelson WW et al (2018) Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. Am J Hematol 93(5):664\u2013671","journal-title":"Am J Hematol"},{"key":"1_CR38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.thromres.2017.02.003","volume":"152","author":"I Theberge","year":"2017","unstructured":"Theberge I, Bowdridge J, Forgie MA, Carrier M, Louzada M, Siquiera L et al (2017) Rivaroxaban shows promise as effective therapy for cancer patients with venous thromboembolic disease. Thromb Res 152:4\u20136","journal-title":"Thromb Res"},{"issue":"4","key":"1_CR39","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s11239-017-1478-0","volume":"43","author":"S Mantha","year":"2017","unstructured":"Mantha S, Miao Y, Wills J, Parameswaran R, Soff GA (2017) Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study. J Thromb Thrombolysis 43(4):514\u2013518","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"1_CR40","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Vainchenker W (2011) Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 29(5):573\u2013582","journal-title":"J Clin Oncol"}],"container-title":["Cancer Treatment and Research","Thrombosis and Hemostasis in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-20315-3_1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T20:54:02Z","timestamp":1663966442000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-20315-3_1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9783030203146","9783030203153"],"references-count":40,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-20315-3_1","relation":{},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"value":"0927-3042","type":"print"},{"value":"2509-8497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"18 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}